KR20200064101A - 질소 함유 헤테로아릴 화합물 및 그의 의약 용도 - Google Patents

질소 함유 헤테로아릴 화합물 및 그의 의약 용도 Download PDF

Info

Publication number
KR20200064101A
KR20200064101A KR1020207012149A KR20207012149A KR20200064101A KR 20200064101 A KR20200064101 A KR 20200064101A KR 1020207012149 A KR1020207012149 A KR 1020207012149A KR 20207012149 A KR20207012149 A KR 20207012149A KR 20200064101 A KR20200064101 A KR 20200064101A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207012149A
Other languages
English (en)
Korean (ko)
Inventor
히로노부 나가모리
다츠야 니시마루
마사키 다카기
이쿠오 미타니
유이치 나카가와
Original Assignee
니뽄 다바코 산교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니뽄 다바코 산교 가부시키가이샤 filed Critical 니뽄 다바코 산교 가부시키가이샤
Publication of KR20200064101A publication Critical patent/KR20200064101A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020207012149A 2017-10-04 2018-10-03 질소 함유 헤테로아릴 화합물 및 그의 의약 용도 Withdrawn KR20200064101A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017194005 2017-10-04
JPJP-P-2017-194005 2017-10-04
PCT/JP2018/037007 WO2019069973A1 (ja) 2017-10-04 2018-10-03 含窒素ヘテロアリール化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
KR20200064101A true KR20200064101A (ko) 2020-06-05

Family

ID=65994698

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207012149A Withdrawn KR20200064101A (ko) 2017-10-04 2018-10-03 질소 함유 헤테로아릴 화합물 및 그의 의약 용도

Country Status (19)

Country Link
US (1) US10752596B2 (https=)
EP (1) EP3693358B1 (https=)
JP (1) JP7125882B2 (https=)
KR (1) KR20200064101A (https=)
CN (1) CN111148735B (https=)
AR (1) AR113270A1 (https=)
AU (1) AU2018345221A1 (https=)
BR (1) BR112020004857A2 (https=)
CA (1) CA3074989A1 (https=)
CL (1) CL2020000898A1 (https=)
CO (1) CO2020003977A2 (https=)
IL (1) IL273573A (https=)
MX (1) MX2020003816A (https=)
PE (1) PE20200846A1 (https=)
PH (1) PH12020550403A1 (https=)
RU (1) RU2020115045A (https=)
SG (1) SG11202003005PA (https=)
TW (1) TW201922706A (https=)
WO (1) WO2019069973A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110156698B (zh) * 2019-06-06 2020-10-13 沈阳海诺威医药科技有限公司 2-苯基-1，6-二氢嘧啶-5-甲酸衍生物的制备方法和用途
CN113181206B (zh) * 2021-04-30 2023-07-14 青岛大学 与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用
IL313713A (en) * 2022-01-07 2024-08-01 Horizon Therapeutics Ireland Dac Heterocyclic inhibitors of glut9 for treatment of disease
CN114805192B (zh) * 2022-03-30 2023-05-23 华南理工大学 一种含2-羟基苯甲酸的三环类xor/urat1双重抑制剂及其制备方法与应用
WO2024167952A1 (en) * 2023-02-08 2024-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oxidatively cleavable organophosphate drugs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
IL127441A (en) * 1996-07-18 2003-02-12 Merck Frosst Canada Inc Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors
PL343424A1 (en) * 1998-04-10 2001-08-13 Japan Tobacco Inc Amidine compounds
WO2005013907A2 (en) * 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
TW200716594A (en) 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
JP2007176933A (ja) * 2005-11-29 2007-07-12 Tanabe Seiyaku Co Ltd 医薬組成物
JP5162827B2 (ja) 2005-12-27 2013-03-13 ぺんてる株式会社 鉛筆芯の製造方法
JP5330990B2 (ja) 2007-04-11 2013-10-30 キッセイ薬品工業株式会社 含窒素複素環化合物およびそれを含有する医薬組成物
JP2009016193A (ja) * 2007-07-05 2009-01-22 Daihen Corp 電気機器用樹脂ブッシング
EP3594213A1 (en) * 2009-07-17 2020-01-15 Japan Tobacco Inc. Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers
CA2794266C (en) 2010-03-24 2020-09-08 Ohio University Compositions and methods for glucose transport inhibition
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CN105439946B (zh) 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
CN104306363B (zh) * 2014-10-31 2017-06-06 南京葆赫生物技术有限公司 芪类衍生物及其药学可接受的盐在制备治疗高尿酸血症药物中的应用

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
ADMET & DMPK. 2017; 5(2):59-74.
Am J Dermatopathol. 1981 Winter; 3(4):397-404.
Am J Hum Genet. 2008 Dec; 83(6):744-51.
Am J Kidney Dis. 2004 Oct; 44(4):642-50.
Am J Kidney Dis. 2015 Dec; 66(6):945-50.
Ann Rheum Dis. 2013 Aug; 72(8):1321-7.
Arch Dermatol. 2008 Nov; 144(11):1518-9.
Biochem Biophys Res Commun. 2014 May 16; 447(4):707-14.
BMJ. 2013 Oct 15; 347:f5961.
Br J Rheumatol. 1994 Aug; 33(8):731-4.
Clin J Am Soc Nephrol. 2014 Jun 6; 9(6):1059-65.
Coron Artery Dis. 2014 Jun; 25(4):343-8.
Genomics. 2000 Jun 1; 66(2):217-20.
Hypertens Res. 2014 Aug; 37(8):785-9.
Hypertension. 2006 Dec; 48(6):1031-6.
Int J Cardiol. 2011 Sep 1; 151(2):143-7.
J Am Soc Nephrol. 2008 Dec; 19(12):2407-13.
J Biol Chem. 2008 Oct 3; 283(40):26834-8.
J Clin Endocrinol Metab. 2015 Nov; 100(11):4198-207.
JAMA. 2008 Aug 27; 300(8):924-32.
Mol Cell Endocrinol. 2013 Aug 15; 375(1-2):89-96.
Nat Genet. 2008 Apr; 40(4):437-42.
National Health and Nutrition Examination Survey. JAMA. 2000 May 10; 283(18):2404-10.
Nephrol Dial Transplant. 2012 Mar; 27(3):1035-41.
PLoS Genet. 2007 Nov; 3(11):e194.
PLoS One. 2013; 8(2):e56864.
PLoS One. 2014 Jun 24; 9(6):e100801.
Ther Res 33:1397-1405, 2012
일본 통풍·핵산 대사 학회 가이드 라인 개정 위원회 편:고요산 혈증·통풍의 치료 가이드 라인(제2판). 오사카, 메디컬 리뷰사, 2010

Also Published As

Publication number Publication date
US10752596B2 (en) 2020-08-25
CA3074989A1 (en) 2019-04-11
SG11202003005PA (en) 2020-04-29
CN111148735B (zh) 2023-08-08
TW201922706A (zh) 2019-06-16
AU2018345221A1 (en) 2020-05-07
PE20200846A1 (es) 2020-08-18
PH12020550403A1 (en) 2021-02-15
JP2019065009A (ja) 2019-04-25
BR112020004857A2 (pt) 2020-09-15
RU2020115045A (ru) 2021-11-08
EP3693358B1 (en) 2023-02-22
EP3693358A1 (en) 2020-08-12
CL2020000898A1 (es) 2020-08-14
JP7125882B2 (ja) 2022-08-25
EP3693358A4 (en) 2021-06-02
CO2020003977A2 (es) 2020-04-24
US20190152926A1 (en) 2019-05-23
IL273573A (en) 2020-05-31
CN111148735A (zh) 2020-05-12
MX2020003816A (es) 2020-08-13
WO2019069973A1 (ja) 2019-04-11
AR113270A1 (es) 2020-03-11

Similar Documents

Publication Publication Date Title
JP7125882B2 (ja) 含窒素ヘテロアリール化合物およびその医薬用途
EP3349761B1 (en) Hepatitis b core protein modulators
JP6976618B2 (ja) 活性酸素種スカベンジャーの調製および使用
CN107108478B (zh) Urat1抑制剂
JP2010511635A (ja) Ｈｉｖ複製の阻害剤
KR20160113727A (ko) 트리아진 화합물 및 그의 의약 용도
JP2024050645A (ja) ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
KR20170016988A (ko) 할로겐 치환 헤테로환 화합물의 염
KR20200115566A (ko) 질소 함유 복소환 아미드 화합물 및 그의 의약 용도
KR20220143062A (ko) 신규 ep4 길항제의 합성 및 암과 염증에서의 이의 용도
WO2020156459A1 (zh) 吡咯并嘧啶衍生物及其用途
KR101821516B1 (ko) 다중 치환된 피리딘 화합물, 그 제조 방법, 용도 및 약학적 조성물
EP2448584B1 (en) Substituted 4-hydroxypyrimidine-5-carboxamides
ES2965041T3 (es) Composiciones para el tratamiento de la fibrosis pulmonar
WO2012006955A1 (en) Compounds for treatment of metabolic disorders
KR101764458B1 (ko) 치환 피리딘 화합물
JP4749335B2 (ja) イミダゾピリジン化合物
HK40027595A (en) Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof
US20250195518A1 (en) Indazole compound and pharmaceutical use thereof
HK40123212A (en) Indazole compound and pharmaceutical use thereof
JP2018505897A (ja) ピラゾール化合物
CN121693498A (zh) 一种4-苯基哌啶衍生物及其应用
WO2022037601A1 (zh) 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200427

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid